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Background
Concurrent treatment with temozolomide and radiotherapy followed by maintenance 
temozolomide is the standard of care for patients with newly diagnosed glioblastoma. 
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth 
factor A, is currently approved for recurrent glioblastoma. Whether the addition of 
bevacizumab would improve survival among patients with newly diagnosed glio-
blastoma is not known.
Methods
In this randomized, double-blind, placebo-controlled trial, we treated adults who had 
centrally confirmed glioblastoma with radiotherapy (60 Gy) and daily temozolomide. 
Treatment with bevacizumab or placebo began during week 4 of radiotherapy and 
was continued for up to 12 cycles of maintenance chemotherapy. At disease progres-
sion, the assigned treatment was revealed, and bevacizumab therapy could be initiated 
or continued. The trial was designed to detect a 25% reduction in the risk of death and 
a 30% reduction in the risk of progression or death, the two coprimary end points, 
with the addition of bevacizumab.
Results
A total of 978 patients were registered, and 637 underwent randomization. There was 
no significant difference in the duration of overall survival between the bevaciz u mab 
group and the placebo group (median, 15.7 and 16.1 months, respectively; hazard 
ratio for death in the bevacizumab group, 1.13). Progression-free survival was longer 
in the bevacizumab group (10.7 months vs. 7.3 months; hazard ratio for progression 
or death, 0.79). There were modest increases in rates of hypertension, thromboembolic 
events, intestinal perforation, and neutropenia in the bevacizumab group. Over time, 
an increased symptom burden, a worse quality of life, and a decline in neurocognitive 
function were more frequent in the bevacizumab group.
Conclusions
First-line use of bevacizumab did not improve overall survival in patients with new-
ly diagnosed glioblastoma. Progression-free survival was prolonged but did not 
reach the prespecified improvement target. (Funded by the National Cancer Institute; 
ClinicalTrials.gov number, NCT00884741.)
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Glioblastoma is the most common primary malignant brain tumor in adults. After maximal surgical tumor resection, 
the current standard of care is based on a phase 3, 
randomized clinical trial conducted by the Euro-
pean Organization for Research and Treatment of 
Cancer and the National Cancer Institute of Can-
ada, which showed that concurrent treatment with 
daily temozolomide and radiotherapy followed by 
maintenance temozolomide was superior to radio-
therapy alone.1,2
Despite the improvement in outcomes with 
this combined chemoradiotherapy approach, few 
patients survive beyond 5 years; therefore, new 
therapeutic strategies are needed.3 Angiogenesis is 
a prominent feature of glioblastoma, most com-
monly attributed to the autocrine and paracrine 
production of vascular endothelial growth factor A 
(VEGF-A), which up-regulates the VEGF signal-
transduction pathway.4,5 Several approaches have 
been used to target this prominent component 
of the tumor biology. Small-molecule tyrosine 
kinase inhibitors of this pathway, such as cedira-
nib and sorafenib, have shown minimal efficacy.6,7 
Bevacizumab is a humanized monoclonal anti-
body against the VEGF-A ligand that binds to its 
circulating target, altering the kinetics of ligand 
binding to endothelial cells and down-regulating 
angiogenesis.8 Initial studies that explored the 
efficacy of bevacizumab in adults with recurrent 
glioblastoma showed clinical activity, including 
a reduction in tumor size, a prolongation of 
progression-free survival, and an overall lower-
ing of glucocorticoid requirements to control 
tumor-related edema.9,10 These results led to 
the accelerated Food and Drug Administration 
approval of bevacizumab for patients with re-
current glioblastoma.
Preclinical models suggest that antiangiogenic 
therapies cause temporary vascular normalization, 
leading to improved blood flow, which in turn 
should improve the delivery of oxygen and chemo-
therapeutic agents, potentially enhancing the ef-
ficacy of both radiotherapy and chemotherapy.11 
As a collaborative effort of the Radiation Therapy 
Oncology Group (RTOG), the North Central Can-
cer Treatment Group (NCCTG), and the Eastern 
Cooperative Oncology Group (ECOG), we con-
ducted a randomized, placebo-controlled, double-
blind, phase 3 trial, called RTOG 0825, to test 
the hypothesis that antiangiogenic therapy im-
proves the efficacy of the standard chemoradio-
therapy for glioblastoma.
Me thods
Study Patients
Patients were eligible for the study if they were at 
least 18 years of age and had newly diagnosed 
glioblastoma (World Health Organization [WHO] 
grade IV astrocytoma), as confirmed on central 
review. Additional eligibility criteria included a 
Karnofsky performance status of at least 70 (on a 
scale from 0 to 100, with higher numbers indi-
cating a higher activity level) and adequate hema-
tologic, renal, and hepatic function (Table S1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). Patients with 
active cardiac disease or recent cerebrovascular 
events were excluded. In addition, patients were 
required to undergo an imaging study (computed 
tomography [CT] or magnetic resonance imaging 
[MRI]) performed within 1 week before study 
registration) to rule out recent intracranial hem-
orrhage. Patients who were receiving glucocorti-
coids had to have received a stable or decreasing 
dose for the 5 days before study registration. 
Also required was the submission of a paraffin- 
embedded tumor-tissue block with a minimum 
of 1 cm2 of tumor surface area before the initia-
tion of radiotherapy.
All patients provided written informed consent. 
The study was approved by the institutional review 
board or the equivalent panel at each study cen-
ter before patient enrollment.
Study Treatment
Patients had to be registered before the start of 
the concomitant radiotherapy and chemotherapy 
(for details, see Fig. S1 in the Supplementary Ap-
pendix). Fractionated, conformal radiotherapy 
or intensity-modulated radiotherapy (IMRT) was 
given at a daily dose of 2 Gy. Treatment was de-
livered 5 days a week for 6 weeks, for a total dose 
of 60 Gy. Conformal therapy was delivered to an 
initial volume consisting of the area of enhance-
ment, the postoperative cavity plus surrounding 
edema (or other abnormality as seen on fluid-
attenuated inversion recovery [FLAIR] images 
on MRI), and a 2-cm margin, for a total dose of 
46 Gy in 23 fractions, followed by a boost of 
14 Gy in 7 fractions to the area of enhancement 
plus the cavity and a 2.5-cm margin. IMRT was 
permitted within protocol-defined guidelines at 
institutions that fulfilled IMRT-specific quality 
requirements, and all patients underwent radio-
therapy quality assurance with the use of pre-
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on September 12, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
A R andomized Trial of Bevacizumab for Glioblastoma
n engl j med 370;8 nejm.org february 20, 2014 701
defined guidelines. Treatment with temozolomide, 
at a dose of 75 mg per square meter of body-
surface area, was started at the initiation of radio-
therapy and was continued daily until the comple-
tion of radiotherapy, with a maximum of 49 doses.
Patients were randomly assigned to receive 
either bevacizumab or placebo in a permuted-
block design.12 Stratification factors were status 
with respect to O-6-methylguanine–DNA methyl-
transferase (MGMT) and a tumor-based molecular 
profile based on expression of nine genes.13 MGMT 
status was determined with the use of a quan-
titative methylation-specific polymerase-chain-
reaction (PCR) assay performed centrally by 
OncoMethylome Sciences.14 The nine-gene assay 
was performed with the use of a PCR technique 
optimized for paraffin-embedded tumor samples, 
and results were dichotomized as either favor-
able or unfavorable.13
Bevacizumab (or placebo) was administered 
intravenously at a dose of 10 mg per kilogram of 
body weight every 2 weeks, starting at week 4 
of radiotherapy, until disease progression, se-
vere treatment-related toxicity, or completion of 
adjuvant therapy (maximum number of doses, 
24 over 12 cycles).
Maintenance treatment with temozolomide 
began 4 weeks after the completion of radio-
therapy at a starting dose of 150 mg per square 
meter for 5 consecutive days of a 28-day cycle, 
with an increase to 200 mg per square meter for 
subsequent cycles if no treatment-related adverse 
events of grade 2 or higher were noted. Treat-
ment was planned for 6 cycles with the option of 
extension to a total of 12 cycles if there were no 
or only low-grade adverse events and there was 
evidence of continued benefit. Antiemetic therapy 
with the use of a 5-hydroxytryptamine receptor 
antagonist was strongly recommended. Pneumo-
cystis prophylaxis was recommended for patients 
with CD4 counts of less than 200 per cubic mil-
limeter. At the time of tumor progression, patients 
could be informed about their study-group assign-
ment and either begin or continue a bevacizumab-
containing regimen provided as part of the study.
Patient Evaluation and Follow-up
At baseline, all the patients underwent a physical 
examination that included a neurologic assessment, 
complete blood counts, blood chemical analyses 
(including tests of renal and hepatic function), 
and tumor imaging with either MRI (preferred) 
or CT, as well as a serum pregnancy test in women 
of child-bearing age. Patients were invited to par-
ticipate in a longitudinal evaluation of the net 
clinical benefits of the treatment (NCB substudy) 
with the use of the M.D. Anderson Symptom 
 Inventory–Brain Tumor Module (MDASI-BT), a 
neurocognitive-function test battery (Hopkins Ver-
bal Learning Test-Revised [HVLT-R], Trail Making 
Test [TMT], and Controlled Oral Word Associa-
tion [COWA]), and the European Organization 
for Research and Treatment of Cancer quality-
of-life questionnaire with a brain-cancer mod-
ule (EORTC QLQ-C30/BN20).15-18 Patients were 
administered the NCB substudy measures at the 
time of imaging studies. During radiotherapy, 
patients were assessed for adverse events weekly 
and underwent weekly complete blood counts and 
monthly blood chemical analyses. During the main-
tenance phase of treatment, patients underwent 
blood counts and blood chemical analyses on 
days 21 and 28 of each cycle.
A repeat tumor-imaging study was performed 
approximately 4 weeks after completion of radio-
therapy and then before the initiation of cycle 4 
of maintenance treatment (as well as before the 
initiation of cycles 7 and 10, if administered). 
Patients who completed adjuvant treatment un-
derwent tumor imaging every 3 months until 
tumor progression. Response was assessed with 
the use of serial measures of the product of the 
two largest cross-sectional diameters, and pro-
gression was defined as an increase in tumor 
size by at least 25% or the development of a new 
lesion.19 Since early reactions to radiotherapy 
may emulate tumor progression, investigators 
were encouraged not to declare tumor progres-
sion within the first 12 weeks after completion 
of radiotherapy unless there was a new lesion or 
neurologic worsening.20 Toxic effects were re-
corded and graded according to the National 
Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE), version 3.0.
Primary End Points
The coprimary end points were the duration of 
overall survival from randomization, which was 
defined as the time until death from any cause, 
and the duration of progression-free survival, 
which was defined as the time until either dis-
ease progression or death.
Study Oversight
The trial, which was sponsored by the National 
Cancer Institute (which also provided the study 
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drug), was developed by the first and last authors 
in collaboration with the RTOG Brain Committee, 
the RTOG Statistical Group, the Cancer Therapy 
Evaluation Program at the National Cancer Insti-
tute, the NCCTG, and the ECOG. An unrestricted 
educational grant for support of the study was 
provided by Genentech, which had no role in the 
collection of data, analysis of findings, or prepa-
ration of this report. All treatment data were col-
lected by the RTOG data center and reviewed by 
the first author. The analyses were performed by 
RTOG statisticians. Central review was per-
formed on all pathological specimens. The first 
draft of the manuscript was written by the first 
author with support from all coauthors; all au-
thors reviewed and approved the manuscript. 
No one who is not an author contributed to the 
preparation of the manuscript. All the authors 
vouch for the completeness and accuracy of the 
data and confirm that the study was conducted 
according to the protocol, which is available 
at NEJM.org.
Statistical Analysis
The trial was designed to concurrently provide a 
power of 80% for the detection of a 25% relative 
reduction in the risk of death (hazard ratio, 0.75) 
and a 30% relative reduction in the risk of either 
disease progression or death (hazard ratio, 0.70) 
in the bevacizumab group as compared with 
the placebo group. To control for type I errors 
in testing for the coprimary end points by 
means of the log-rank test,21 the threshold for 
statistical significance was set at a two-sided 
P value of 0.046 for overall survival and 0.004 
for pro gression-free survival. The enrollment goal 
was 612 eligible patients, and a definitive analy-
sis would be performed after 390 deaths had oc-
curred. Interim monitoring with early stopping 
criteria for efficacy and futility was performed, 
as described in the study protocol, and was over-
seen by the RTOG data and safety monitoring 
committee.
We used the Kaplan–Meier method to estimate 
survival distributions and a Cox proportional-
hazards model to calculate hazard ratios.22,23 To 
determine whether a molecularly defined sub-
group had a selective survival benefit from the 
addition of bevacizumab to standard treatment, 
we performed protocol-specified subset analyses 
for each tumor molecular factor and for combi-
nations of molecular profile and MGMT status. 
We used the Cox model to perform additional 
analyses that examined the effects of these fac-
tors and recursive partitioning analysis (RPA) 
class,13 a compilation of clinical factors that de-
fine a patient’s prognosis, with classes ranging 
from I to VI and higher classes indicating a 
worse prognosis. This study enrolled patients in 
RPA classes III, IV, and V. For all these analyses, 
we used a likelihood-ratio test to evaluate differ-
ential treatment effects (interactions). We evalu-
ated the proportionality of hazards using a test 
based on model residuals and smoothed hazard 
plots.24,25
In the NCB substudy,18 we assessed net clinical 
benefits to determine whether there were differ-
ences in changes between the two study groups 
from baseline to week 46 in patient-reported 
outcomes (on the basis of the MDASI-BT and 
EORTC QLQ-C30/BN20) or neurocognitive func-
tion (HVLT-R, TMT, and COWA). As specified 
in the trial protocol, these analyses were re-
stricted to patients who were deemed to be 
progression-free at the time of the assessment. 
General linear models were used for longitudinal 
assessments, with fixed effects for study group 
and time factors and inclusion of MGMT status 
and RPA class to adjust for prognostic status. A 
treatment-by-time interaction effect was added 
to the model to determine whether there were 
between-group differences in patterns of response 
over time, with a P value of 0.05 considered to 
indicate statistical significance.
R esult s
Study Patients
From April 2009 through May 2011, we enrolled 
978 patients, of whom 341 were deemed to be in-
eligible or otherwise unable to undergo randomiza-
tion (Fig. 1). Patients who underwent randomization 
had clinical characteristics that were similar to 
those who did not undergo randomization (Table S2 
in the Supplementary Appendix). A total of 637 pa-
tients (65% of those who were enrolled and 96% of 
those who were deemed to be eligible) were ran-
domly assigned to receive either placebo (317 pa-
tients) or bevacizumab (320 patients); 621 patients 
were included in the final analysis. One patient 
who was found to have disease progression be-
fore randomization was not included in the analy-
sis of progression-free survival. Baseline char-
acteristics were well balanced between the two 
study groups (Table S3 in the Supplementary Ap-
pendix). The characteristics of patients who con-
The New England Journal of Medicine 
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sented to participate in the NCB substudy did not 
differ from the characteristics of those who were 
unwilling or unable to participate (Table S4 in 
the Supplementary Appendix). More than 80% of 
the patients who underwent randomization con-
sented to participate in the assessment of net 
clinical benefits. Only 20 patients could not par-
ticipate because of native language constraints 
666 Were eligible to undergo randomization
978 Patients were assessed for eligibility
312 Were excluded
105 Had insufficient tissue
40 Had blood on scan
32 Declined to participate
24 Did not qualify
23 Had laboratory results out of range
16 Had concurrent illness
13 Had nonadherence to specified timeline
12 Had progressive disease
7 Had incomplete imaging
6 Had multifocal disease
6 Had adverse events
6 Had insurance issues
3 Were withdrawn by physician
3 Died
1 Was in wrong study
15 Had other reasons
637 Underwent randomization
29 Did not undergo randomization
7 Declined to participate
4 Had disease progression
4 Had nonadherence to specified 
   timeline
2 Had adverse events
2 Were withdrawn by physician
2 Had insurance issues
1 Died
1 Had incomplete imaging
1 Had clinical decline
1 Had other disease
1 Was ineligible
1 Did not have MGMT data
2 Had other reasons
317 Were assigned to receive
placebo
320 Were assigned to receive
bevacizumab
8 Were excluded
2 Had incomplete imaging 
3 Had blood on scan
2 Had nonadherence to 
   specified timeline
1 Underwent stereotactic 
   biopsy
8 Were excluded
4 Had incomplete imaging
4 Had nonadherence to 
   specified timeline
309 Were included in the analysis 312 Were included in the analysis
Figure 1. Enrollment and Outcomes.
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(Table S5 in the Supplementary Appendix). The 
rate of completion of the test instruments re-
mained high from baseline to week 46 (Table S7 
in the Supplementary Appendix).
Study Treatment
In the bevacizumab group, 163 of 312 patients 
(52.2%) received at least 6 cycles of treatment 
(median number, 6). In the placebo group, 110 of 
309 patients (35.6%) received at least 6 cycles of 
maintenance treatment (median number, 3). The 
full 12 cycles were administered in 57 patients 
(18.3%) in the bevacizumab group and in 59 pa-
tients (19.1%) in the placebo group. Tumor pro-
gression or death prompted treatment cessation 
in 73 of 268 patients (27.2%) in the bevacizumab 
group and in 135 of 274 patients (49.3%) in the 
placebo group. Toxicity or intercurrent illness re-
sulted in treatment cessation in 88 patients (32.8%) 
in the bevacizumab group and in 45 patients 
(16.4%) in the placebo group.
At the time of this analysis, the treatment as-
signment had been revealed for 155 of 320 pa-
tients (48.4%) in the bevacizumab group and 178 
of 317 patients (56.2%) in the placebo group. 
Among patients with disease progression, sal-
vage treatment was planned for 87 of 155 patients 
(56.1%) in the bevacizumab group and 128 of 
178 patients (71.9%) in the placebo group. Among 
these patients, the protocol-related bevacizumab 
regimen was continued in 39 patients (25.2%) in 
the bevacizumab group and was started in 86 pa-
tients (48.3%) in the placebo group.
Treatment Outcomes
Primary Analysis
At the time of analysis (December 2012), 208 of 
the 621 patients who were included in the pri-
mary analysis (33.5%) were still alive, with a me-
dian follow-up time of 20.5 months. The median 
overall survival was 15.7 months (95% confidence 
interval [CI], 14.2 to 16.8) in the bevacizumab 
group and 16.1 months (95% CI, 14.8 to 18.7) in 
the placebo group (hazard ratio for death in the 
bevacizumab group, 1.13; 95% CI, 0.93 to 1.37; 
P = 0.21 by the log-rank test) (Fig. 2A).
Tumor progression or death occurred in 
512 patients (82.4%). The median duration 
of progression-free survival was 10.7 months 
(95% CI, 10.0 to 12.2) in the bevacizumab 
group as compared with 7.3 months (95% CI, 
5.9 to 7.9) in the placebo group (hazard ratio 
for progression or death, 0.79; 95% CI, 0.66 
to 0.94; P = 0.007 by the log-rank test) (Fig. 2B). 
The treatment effect for progression-free survival 
varied over time (P<0.001 for proportionality of 
hazards).
MGMT Status, Molecular Profile, and RPA Class
MGMT status was prognostic regardless of the 
study treatment. The median overall survival was 
14.3 months (95% CI, 13.6 to 15.3) for patients 
with MGMT unmethylated tumors as compared 
with 23.2 months (95% CI, 20.1 to 28.3) for 
those with methylated tumors (hazard ratio for 
death in patients with unmethylated tumors, 2.10; 
95% CI, 1.65 to 2.68; P<0.001). The median pro-
gression-free survival was 8.2 months (95% CI, 
7.5 to 9.2) for patients with MGMT unmethylated 
tumors and 14.1 months (95% CI, 10.5 to 16.1) 
for those with methylated tumors (hazard ratio, 
1.67; 95% CI, 1.36 to 2.05; P<0.001).
The nine-gene assay, which was developed in 
a separate trial involving more than 500 patients 
with glioblastoma who did not receive bevaciz-
umab, was not prognostic in either study group 
on the basis of a specific favorable or unfavorable 
categorization of continuous data and a uniform 
setting of analytic specifications.
The RPA class was prognostic regardless of the 
study treatment. The median duration of overall 
survival was 20.1 months (95% CI, 16.7 to 35.7) 
for patients in class III, 15.6 months (95% CI, 
14.6 to 17.2) for those in class IV, and 13.2 months 
(95% CI, 10.2 to 14.6) for those in class V 
(P<0.001). The median progression-free survival 
was 12.5 months (95% CI, 9.1 to 16.6) for patients 
in class III, 9.6 months (95% CI, 8.5 to 10.4) for 
those in class IV, and 7.1 months (95% CI, 5.3 to 
8.7) for those in class V (P = 0.001). Subset analy-
ses that were based on the individual molecular 
components as well as various combinations of 
MGMT status and molecular profile were per-
formed. No subset had improved survival with 
the addition of bevacizumab. These treatment 
effects were similar across RPA classes (Table 1).
Similarly, treatment effects after adjustment 
for MGMT status, molecular profile, and RPA 
class were unchanged: hazard ratio for death, 
1.12 (95% CI, 0.91 to 1.37; P = 0.30); and hazard 
ratio for disease progression or death, 0.80 
(95% CI, 0.66 to 0.97; P = 0.02). Testing for sta-
tistical interaction did not identify a significant 
differential effect of treatment according to 
combinations of MGMT status and molecular 
profiles or those factors individually.
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Net Clinical Benefits
In the NCB substudy, we found greater deterio-
ration over time in the bevacizumab group than 
in the placebo group on the basis of the 
 between-group difference in the composite 
scores on the neurocognitive-function test bat-
tery (P = 0.05), as well as the scores for the Con-
trolled Oral Word Association Test (P = 0.003) 
and the Trail Making Test, Part A (P = 0.04). 
Longitudinal evaluation also revealed greater 
deterioration in the bevacizumab group on the 
basis of the MDASI-BT composite symptom 
score (P = 0.02), composite symptom-interference 
score (P<0.001), and the scores for activity-related 
symptom interference (P = 0.004), mood-related 
symptom interference (P<0.001), affective factors 
(P = 0.04), cognitive factors (P = 0.01), treatment 
factors (P = 0.03), and generalized or disease fac-
tors (P = 0.01), as well as EORTC QLQ-C30/BN20 
scores for cognitive functioning (P = 0.008), motor 
dysfunction (P = 0.02), and communication defi-
cit (P = 0.003) (Table S8 in the Supplementary 
Appendix).
Safety and Toxicity
Safety and toxicity data were available for 300 pa-
tients in the placebo group and 303 patients in the 
bevacizumab group. During chemoradiotherapy 
with bevacizumab or placebo, serious lymphopenia 
was the most common toxic effect, occurring in 
approximately 10% of patients in the two study 
groups but without clinically significant oppor-
tunistic infection. Serious neutropenia was more 
common in the bevacizumab group than in the 
placebo group (7.3% vs. 3.7%), as was serious 
thrombocytopenia (10.2% vs. 7.7%) (Table 2).
During the maintenance phase, serious adverse 
events were more prevalent in the bevacizumab 
group than in the placebo group, including hyper-
tension (4.2% vs. 0.9%), thromboembolic disease 
(7.7% vs. 4.7%), wound dehiscence (1.5% vs. 0.9%), 
fatigue (13.1% vs. 9.0%), visceral perforation (1.2% 
vs. 0.4%), and serious hemorrhage (1.5% vs. 0.9%). 
Serious neutropenia was more common in the 
bevacizumab group (10.0% vs. 5.1%), but thrombo-
cytopenia was slightly less common (11.1% vs. 
11.7%) (Table 2).
Discussion
Two phase 2 studies have evaluated the use of 
bevacizumab in patients with newly diagnosed 
glioblastoma. Vredenburgh and colleagues treat-
ed 75 patients with radiotherapy, temozolomide, 
and bevacizumab, followed by adjuvant temozolo-
mide, irinotecan, and bevacizumab.26 The median 
overall survival was 21.2 months, which com-
pared favorably with survival in historical con-
trols. These results were very similar to those 
reported by Lai and collaborators, but they com-
pared results in the study patients with those in 
a contemporary group of patients who received 
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Figure 2. Primary End Points, According to Study Group.
The median rates of overall survival were similar in the bevacizumab and 
placebo groups (Panel A). The median rate of progression-free survival was 
higher in the bevacizumab group than in the placebo group but did not 
reach the prespecified threshold for significance (P<0.004) (Panel B).
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standard temozolomide and radiotherapy, which 
showed an improvement in progression-free sur-
vival with bevacizumab (13.6 vs. 7.6 months) but 
not in overall survival (19.6 vs. 21.1 months).27
Our study was designed to determine whether 
adding bevacizumab to the first-line treatment for 
glioblastoma would improve patient outcomes. 
We chose the coprimary end points, overall surviv-
Table 1. Study End Points, According to Genetic, Molecular, and Clinical Prognostic Subgroups.*
End Point and Subgroup Bevacizumab Placebo
Hazard Ratio 
(95% CI)† P Value
mo
All patients
Median overall survival 15.7 16.1 1.13 (0.93–1.30) 0.21
Median progression-free survival 10.7 7.3 0.79 (0.66–0.94) 0.007
MGMT status and molecular profile
Methylated MGMT
Favorable molecular profile
Median overall survival 16.7 25.0 2.27 (0.91–5.68) 0.07
Median progression-free survival 13.0 13.5 1.39 (0.67– 2.89) 0.38
Unfavorable molecular profile
Median overall survival 21.1 25.3 1.24 (0.73–2.12) 0.43
Median progression-free survival 16.9 8.4 0.63 (0.40–0.98) 0.04
Unmethylated MGMT
Favorable molecular profile
Median overall survival 13.9 14.6 1.02 (0.66–1.57) 0.94
Median progression-free survival 10.1 7.3 0.72 (0.48–1.07) 0.10
Unfavorable molecular profile
Median overall survival 14.0 14.6 1.13 (0.86–1.49) 0.36
Median progression-free survival 9.8 5.4 0.86 (0.67–1.11) 0.25
RPA class
III
Median overall survival 20.6 19.8 0.98 (0.54–1.81) 0.96
Median progression-free survival 14.9 9.5 0.74 (0.43–1.25) 0.25
IV
Median overall survival 15.7 15.6 1.14 (0.90–1.44) 0.29
Median progression-free survival 10.8 7.3 0.78 (0.63–0.96) 0.02
V
Median overall survival 12.6 13.3 1.01 (0.66–1.56) 0.96
Median progression-free survival 9.8 4.4 0.70 (0.46–1.06) 0.10
* The recursive-partitioning analysis (RPA) classes are as follows: class III: an age of less than 50 years and a Karnofsky 
performance score of 90 or more (on a scale of 0 to 100, with higher scores indicating better function); class IV, an age 
of less than 50 years and a Karnofsky performance score of less than 90 (or an age of 50 years or more, a Karnofsky 
performance score of 70 or more, a gross total or partial tumor resection, and an ability to work); class V, an age of 50 
years or more, a Karnofsky performance score of 70 or more, a gross total or partial tumor resection, and an inability to 
work (or an age of 50 years or more, a Karnofsky performance score of 70 or more, and tumor-biopsy specimen only; or 
an age of 50 years or more and a Karnofsky performance score of less than 70). CI denotes confidence interval.
† Hazard ratios are for death (for overall survival) and tumor progression or death (for progression-free survival) in the 
bevacizumab group, as compared with the placebo group.
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al and progression-free survival, because of the 
crossover design of the study. At the time of 
disease progression, the treatment assignment 
in the bevacizumab group could be revealed 
and patients could begin or continue a regimen 
containing bevacizumab. Therefore, the end 
point of overall survival was used to determine 
whether first-line use of bevacizumab was su-
perior to use as a salvage regimen, and the end 
point of progression-free survival was used to 
evaluate the potential early benefits of com-
bined treatment.
We found no benefit in overall survival with 
early administration of bevacizumab. Progression-
free survival was prolonged for the patients receiv-
ing first-line bevacizumab, but the hazard ratio 
(0.79) and P value (0.007) did not reach the pre-
defined criteria. However, we did not assess the 
efficacy of first-line treatment with bevacizumab 
in patients with unresected tumors, since the re-
quirement for a tumor specimen excluded patients 
who had undergone only a diagnostic biopsy. In 
additional analyses of subgroups of patients de-
fined prospectively on the basis of molecular 
markers, we did not identify a subgroup of patients 
who had a selected survival benefit from the early 
administration of bevacizumab. Further investiga-
tions of molecularly defined subgroups may un-
cover a predictive marker panel for beva ciz umab, 
which would require additional prospective testing.
A similar study, Avastin [bevacizumab] in Glio-
blastoma (AVAGlio), which also evaluated the role 
of bevacizumab as first-line treatment in patients 
with newly diagnosed glioblastoma, was recently 
completed.28 That study showed a result for over-
all survival that was similar to our finding but 
showed a different result for progression-free sur-
vival on the basis of a statistical design that in-
cluded a different prespecified alpha level for 
progression (P<0.01). The AVAGlio study also evalu-
ated patient-reported outcomes but restricted those 
data primarily to health-related quality-of-life mea-
sures, whereas we also collected measures of 
symptom burden and interference and the results 
of objective tests of neurocognitive function.
In our study, we evaluated longitudinal changes 
in both objective and patient-reported neurocog-
nitive function and in self-reported quality of life 
and other symptoms in patients who were deemed 
to be progression-free. These assessments consis-
tently showed that patients receiving bevacizu mab, 
as compared with placebo, had greater deteriora-
Table 2. Serious Adverse Events.
Event During Chemoradiotherapy During Adjuvant Treatment
Bevacizumab 
(N = 303)
Placebo 
(N = 300)
Bevacizumab 
(N = 260)
Placebo 
(N = 233)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
number of patients (percent)
Anemia 1 (0.3) 1 (0.3) 1 (0.3) 0 4 (1.5) 2 (0.8) 3 (1.3) 0
Leukopenia 10 (3.3) 6 (2.0) 4 (1.3) 3 (1.0) 20 (7.7) 2 (0.8) 14 (6.0) 0
Neutropenia 7 (2.3) 15 (5.0) 5 (1.7) 6 (2.0) 20 (7.7) 6 (2.3) 7 (3.0) 5 (2.1)
Lymphopenia 24 (7.9) 8 (2.6) 22 (7.3) 5 (1.7) 27 (10.4) 7 (2.7) 23 (10) 8 (3.4)
Thrombocytopenia 10 (3.3) 21 (6.9) 17 (5.7) 6 (2.0) 18 (6.9) 11 (4.2) 23 (10) 4 (1.7)
Fatigue 7 (2.3) 0 8 (2.7) 0 32 (12.3) 2 (0.8) 21 (9.0) 0
Nausea and vomiting 2 (0.7) 0 1 (0.3) 0 11 (4.2) 0 4 (1.7) 0
Wound dehiscence 3 (1.0) 0 1 (0.3) 0 3 (1.2) 1 (0.4) 2 (0.9) 0
Hypertension 4 (1.3) 0 1 (0.3) 0 11 (4.2) 0 2 (0.9) 0
Thromboembolic 
disease
6 (2.0) 8 (2.6) 3 (1.0) 8 (2.7) and  
1 grade 5 
(0.3)
11 (4.2) 8 (3.1) and 
1 grade 5 
(0.4)
7 (3.0) 4 (1.7)
Hemorrhage 0 0 1 (0.3) 0 3 (1.2) 1 grade 5 (0.4) 2 (0.9) 0
Visceral perforation 1 (0.3) 0 0 1 (0.3) 2 (0.8) 1 (0.4) 1 (0.4) 0
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tion in scores on objective tests of neurocognitive 
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er deterioration in the perceived severity of their 
symptoms, as assessed on the basis of both pa-
tient-reported outcomes and symptom-associated 
interference with daily activities.
In conclusion, we did not observe an overall 
survival advantage with first-line use of bevaciz-
u mab in patients with newly diagnosed glioblas-
toma. Furthermore, higher rates of neurocog-
nitive decline, increased symptom severity, and 
decline in health-related quality of life were found 
over time among patients who were treated with 
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